Trial Profile
Pregnancy Outcomes with Trimesters of Maternal Exposure to Certolizumab Pegol: Prospective and Retrospective Reports from Safety Surveillance
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Nov 2015
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis
- Focus Adverse reactions
- 01 Nov 2015 Results published in The Journal of Rheumatology
- 24 Jul 2015 New trial record
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.